Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 1/2016

01-02-2016 | Original Article

Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG)

Authors: Yasumasa Nishimura, Keiichi Jingu, Satoshi Itasaka, Yoshiharu Negoro, Yuji Murakami, Katsuyuki Karasawa, Gen Kawaguchi, Fumiaki Isohashi, Masao Kobayashi, Yoshiyuki Itoh, Takuro Ariga

Published in: International Journal of Clinical Oncology | Issue 1/2016

Login to get access

Abstract

Background

This second questionnaire-based survey was performed to determine the clinical results of definitive esophageal cancer treatment with radiotherapy (RT) or chemoradiotherapy (CRT) between 2004 and 2008.

Materials/methods

Clinical results of definitive RT for patients were collected from major Japanese institutions. Patients were classified into three groups: (A) stage I, (B) resectable stages II–III, (C) unresectable stages III–IVA. For group A, all patients treated with RT alone or CRT were included. For groups B and C, only those treated with CRT were included.

Results

In total, 990 patients (group A 259, group B 333, group C 398 patients) were included from 11 institutions. In group A, 199 patients (78 %) were treated with CRT, and 60 patients (23 %) received RT alone. In groups B and C, 420 patients (57 %) were treated with full-dose cisplatin/5-FU, and 181 patients (25 %) with low-dose protracted-infusion cisplatin/5-FU. The median and range of the 5-year overall survival rate were 73 % (40–94 %) for group A, 40 % (0–57 %) for group B, and 18 % (6–26 %) for group C, respectively. The 5-year overall survival rates were consistently good for five high-volume centers where more than 20 patients/year with esophageal cancer were treated definitively as compared with the remaining six medium-volume centers (5–15 patients/year). The median and range of the incidence of grade ≥3 late toxicities were 10 % and 6–22 %, respectively.

Conclusions

A wide disparity in 5-year overall survival rates among the institutions was still apparent in the second survey for groups A and B.
Literature
1.
Al-Sarraf M, Herskovic A, Martz K et al (1997) Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15:277–284PubMed
2.
Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281:1623–1627CrossRefPubMed
3.
Smith TJ, Ryan LM, Douglass HO Jr et al (1998) Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 42:269–276CrossRefPubMed
4.
Nishimura Y, Suzuki M, Nakamatsu K et al (2002) Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys 53:134–139CrossRefPubMed
5.
Ohtsu A, Boku N, Muro K et al (1999) Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17:2915–2921PubMed
6.
Sakai K, Inakoshi H, Sueyama H et al (1995) Concurrent radiotherapy and chemotherapy with protracted continuous infusion of 5-fluorouracil in inoperable esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 31:921–927CrossRefPubMed
7.
Hironaka S, Ohtsu A, Boku N et al (2003) Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2–3) N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 57:425–433CrossRefPubMed
8.
Murakami M, Kuroda Y, Nakajima T et al (1999) Comparison between chemoradiation protocol intended for organ preservation and conventional surgery for clinical T1–T2 esophageal carcinoma. Int J Radiat Oncol Biol Phys 45:277–284CrossRefPubMed
9.
Ariga H, Nemoto K, Miyazaki S et al (2009) Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 75:348–356CrossRefPubMed
10.
Nishimura Y, Okuno Y, Ono K et al (1999) External-beam radiation therapy with or without high-dose-rate intraluminal brachytherapy for superficial esophageal cancer. Cancer 86:220–228CrossRefPubMed
11.
Sai H, Mitsumori M, Araki N et al (2005) Long-term results of definitive radiotherapy for stage I esophageal cancer. Int J Radiat Oncol Biol Phys 62:1339–1344CrossRefPubMed
12.
Nemoto K, Matsumoto Y, Yamakawa M et al (2000) Treatment of superficial esophageal cancer by external radiation therapy alone: results of a multi-institutional experience. Int J Radiat Oncol Biol Phys 46:921–925CrossRefPubMed
13.
Nemoto K, Yamada S, Hareyama M et al (2001) Radiation therapy for superficial esophageal cancer: a comparison of radiotherapy methods. Int J Radiat Oncol Biol Phys 50:639–644CrossRefPubMed
14.
Kato H, Sato A, Fukuda H et al (2009) A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol 39:638–643CrossRefPubMed
15.
Murakami Y, Kenjo M, Uno T et al (2007) Results of the 1999-2001 Japanese patterns of care study for patients receiving definitive radiation therapy without surgery for esophageal cancer. Jpn J Clin Oncol 37:493–500CrossRefPubMed
16.
Kenjo M, Uno T, Murakami Y et al (2009) Radiation therapy for esophageal cancer in Japan: results of the Patterns of Care Study 1999–2001. Int J Radiat Oncol Biol Phys 75:357–363CrossRefPubMed
17.
Kuwano H, Nishimura Y, Oyama T et al (2015) Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2012 edited by the Japan Esophageal Society. Esophagus 12:1–30
18.
Nishimura Y, Koike R, Ogawa K et al (2012) Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: The Japanese Radiation Oncology Study Group (JROSG) survey. Int J Clin Oncol 17:48–54CrossRefPubMed
19.
Nishimura Y, Hiraoka M, Koike R et al (2012) Long-term follow-up of a randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021). Jpn J Clin Oncol 42:807–812CrossRefPubMed
20.
Sakayauchi T, Nemoto K, Ishioka C et al (2009) Comparison of cisplatin and 5-fluorouracil chemotherapy protocols combined with concurrent radiotherapy for esophageal cancer. Jpn J Radiol 27:131–137
21.
Sai H, Mitsumori M, Yamauchi C et al (2004) Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil. Int J Clin Oncol 9:149–153CrossRefPubMed
22.
Yamada K, Murakami M, Okamoto Y et al (2006) Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal cancer. Int J Radiat Oncol Biol Phys 64:1106–1111CrossRefPubMed
23.
Nemoto K, Matsushita H, Ogawa Y et al (2003) Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. Am J Clin Oncol 26:46–49
24.
Sasamoto R, Sakai K, Inakoshi H et al (2007) Long-term results of chemoradiotherapy for locally advanced esophageal cancer, using daily low-dose 5-fluorouracil and cis-diammine-dichloro-platinum (CDDP). Int J Clin Oncol 12:25–30
25.
Hihara J, Yoshida K, Hamai Y et al (2007) Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer. Anticancer Res 27(4C):2597–2603PubMed
26.
Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167–1174CrossRefPubMed
27.
Shinoda M, Ando N, Kato K et al (2015) Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 106:407–412. doi:10.​1111/​cas.​12622
28.
Fujita H, Ozawa S, Kuwano H et al (2010) Esophagectomy for cancer: clinical concerns support centralization operations within the larger hospitals. Dis Esophagus 23:145–152CrossRefPubMed
29.
Ishikura S, Nihei K, Ohtsu A et al (2003) Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 21:2697–2702CrossRefPubMed
Metadata
Title
Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG)
Authors
Yasumasa Nishimura
Keiichi Jingu
Satoshi Itasaka
Yoshiharu Negoro
Yuji Murakami
Katsuyuki Karasawa
Gen Kawaguchi
Fumiaki Isohashi
Masao Kobayashi
Yoshiyuki Itoh
Takuro Ariga
Publication date
01-02-2016
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 1/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0872-x

Other articles of this Issue 1/2016

International Journal of Clinical Oncology 1/2016 Go to the issue

Original Article

A new prognostic model for chemotherapy-induced febrile neutropenia

Review Article

Strategies for dealing with fraud in clinical trials

Original Article

Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201

Original Article

Keratinized strap cells: a rare cytological atypia resembles Anitschkow cells, in human oral neoplasm

Original Article

Clinical outcome of urachal cancer in Japanese patients

Original Article

Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits